PMID-31294133 – Comparison of GnRH Agonists in Prostate Cancer
Shim M et al. "Comparison of the clinical efficacy of GnRH agonists in prostate cancer," Investigative and Clinical Urology, 2019;60(4):239-247.
Quick Reference
| Property | Value |
|---|---|
| PMID | 31294133 |
| DOI | N/A |
| Year | 2019 |
| Journal | Investigative and Clinical Urology |
| Study Type | Retrospective Observational |
| Evidence Level | III |
| Sample | 125 patients |
| Peptide(s) Studied | Triptorelin, Leuprolide, Goserelin |
Key Findings
- Retrospective comparison of three GnRH agonists (triptorelin, leuprolide, goserelin) in 125 prostate cancer patients receiving androgen deprivation therapy
- Triptorelin achieved the lowest mean testosterone levels among the three agents, suggesting more complete androgen suppression
- All three GnRH agonists effectively suppressed testosterone to castrate levels (<50 ng/dL) in the majority of patients
- PSA response rates were comparable across all three agents
- Time to testosterone nadir was similar across groups
- Adverse event profiles were generally comparable, with injection site reactions and hot flashes being most common across all agents
Study Design
Single-center retrospective chart review comparing clinical outcomes (testosterone levels, PSA response) in prostate cancer patients treated with one of three GnRH agonists. Patients were not randomized; treatment assignment was based on physician preference and insurance coverage.
Limitations
- Retrospective, non-randomized design introduces selection bias
- Small sample size (n=125) limits statistical power for subgroup analyses
- Single-center study limits generalizability
- No long-term oncological outcomes (progression-free survival, overall survival) reported
- Confounding variables (prior treatments, disease stage) not fully controlled
Clinical Relevance
While this study has methodological limitations, it provides comparative real-world data suggesting that triptorelin may achieve slightly superior testosterone suppression among GnRH agonists. This is relevant for practitioners who need to choose between available GnRH agonist formulations. However, the clinical significance of small differences in testosterone suppression within the castrate range remains debated. The finding supports triptorelin as a reasonable choice within the GnRH agonist class.
Related
#research #observational #evidence-level-III #cancer